BRPI0606905A2 - derivados de quinazolina tendo atividade inibitória de tirosina cinase e composição farmacêutica contendo-os - Google Patents

derivados de quinazolina tendo atividade inibitória de tirosina cinase e composição farmacêutica contendo-os

Info

Publication number
BRPI0606905A2
BRPI0606905A2 BRPI0606905-3A BRPI0606905A BRPI0606905A2 BR PI0606905 A2 BRPI0606905 A2 BR PI0606905A2 BR PI0606905 A BRPI0606905 A BR PI0606905A BR PI0606905 A2 BRPI0606905 A2 BR PI0606905A2
Authority
BR
Brazil
Prior art keywords
optionally substituted
hydrogen atom
substituted alkyl
tyrosine kinase
pharmaceutical composition
Prior art date
Application number
BRPI0606905-3A
Other languages
English (en)
Inventor
Masaharu Kume
Kenji Matsuo
Naoki Omori
Masami Takayama
Aiko Omori
Takeshi Endo
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BRPI0606905A2 publication Critical patent/BRPI0606905A2/pt
Publication of BRPI0606905B1 publication Critical patent/BRPI0606905B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS DE QUINAZOLINA TENDO ATIVIDADE INIBITóRIA DE TIROSINA CINASE E COMPOSIçãO FARMACêUTICA CONTENDO-OS. A presente invenção refere-se a um composto que inibe tanto a tirosina cinase do receptor EGF quanto a tirosina cinase HER2. Composto representado pela fórmula geral (I): em que R^ x^ é um grupo representado pela fórmula: em que R^ 1^ é um átomo de hidrogênio, alquila opcionalmente substituida, etc.; Z é -O-, -N(R^ 10^)-, etc.; R^ 10^ é um átomo de hidrogênio, alquila, etc.; R^ 2^ é um átomo de hidrogênio, alquila opcionalmente substituida, etc.; R^ 18^ é um átomo de hidrogênio, alquila opcionalmente substituida, etc.; R^ 19^ é alquila opcionalmente substituida, etc.; W^ 1^ e um grupo contendo nitrogênio não aromático opcionaímente substituído; R^ 17^ é um átomo de hidrogênio, alquila opcionalmente substituida, etc.; R^ 3^ e R^ 4^ são independentemente um átomo de hidrogênio, alquila opcionalmente substituida, etc.; X é -O-, -S-, ou -N(R^ 12^)-, etc.; R^ 2^ é um átomo de hidrogênio, alquila, etc.; e A é fenila opcionalmente tendo um substituinte, etc., seu saí farmaceuticamente aceitável, ou um solvato do mesmo.
BRPI0606905-3A 2005-02-23 2006-02-22 Derivados de quinazolina tendo atividade inibitória de tirosina cinase e composição farmacêutica que os compreende BRPI0606905B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2005047383 2005-02-23
JP2005-047383 2005-02-23
JP2005-156828 2005-05-30
JP2005156828 2005-05-30
PCT/JP2006/303125 WO2006090717A1 (ja) 2005-02-23 2006-02-22 チロシンキナーゼ阻害作用を有するキナゾリン誘導体

Publications (2)

Publication Number Publication Date
BRPI0606905A2 true BRPI0606905A2 (pt) 2009-07-28
BRPI0606905B1 BRPI0606905B1 (pt) 2021-06-01

Family

ID=36927355

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606905-3A BRPI0606905B1 (pt) 2005-02-23 2006-02-22 Derivados de quinazolina tendo atividade inibitória de tirosina cinase e composição farmacêutica que os compreende

Country Status (16)

Country Link
US (2) US8202879B2 (pt)
EP (1) EP1854789B1 (pt)
JP (1) JP4137174B2 (pt)
KR (1) KR100910333B1 (pt)
CN (1) CN101163684B (pt)
AU (1) AU2006216266C1 (pt)
BR (1) BRPI0606905B1 (pt)
CA (1) CA2599328C (pt)
DK (1) DK1854789T3 (pt)
ES (1) ES2431843T3 (pt)
NO (1) NO343403B1 (pt)
PL (1) PL1854789T3 (pt)
PT (1) PT1854789E (pt)
RU (1) RU2414457C2 (pt)
TW (1) TWI372147B (pt)
WO (1) WO2006090717A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006090717A1 (ja) * 2005-02-23 2006-08-31 Shionogi & Co., Ltd. チロシンキナーゼ阻害作用を有するキナゾリン誘導体
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
US7547781B2 (en) * 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033749A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Quinazoline based egfr inhibitors containing a zinc binding moiety
EP2365962B1 (en) 2008-11-07 2017-07-05 Massachusetts Institute of Technology Aminoalcohol lipidoids and uses thereof
TWI466872B (zh) * 2008-12-25 2015-01-01 Shionogi & Co 喹唑啉衍生物之製造方法
KR102451116B1 (ko) * 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
CN103288756B (zh) * 2012-02-29 2016-04-20 江苏先声药物研究有限公司 一种喹唑啉中间体的甲醇溶剂合物及其制备方法
CN105407894A (zh) 2013-03-14 2016-03-16 康威基内有限公司 用于抑制含布罗莫结构域的蛋白质的方法和组合物
JP6099182B2 (ja) * 2014-05-29 2017-03-22 塩野義製薬株式会社 アルキニルケトン誘導体の製造方法
JP6334065B2 (ja) * 2015-07-29 2018-05-30 塩野義製薬株式会社 キナゾリン誘導体の塩またはその結晶およびそれらの製造方法
CA3000988A1 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN115806550A (zh) * 2015-11-25 2023-03-17 康威基内有限公司 双环bet布罗莫结构域抑制剂及其用途
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
JP7191446B2 (ja) * 2017-01-30 2022-12-19 塩野義製薬株式会社 キナゾリン誘導体を含有する固形製剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
EP3103799B1 (en) * 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
HUP0204413A3 (en) 1999-09-21 2003-07-28 Astrazeneca Ab Quinazoline compounds, their preparation, their use and pharmaceutical compositions containing them
CN1264824C (zh) 2001-02-21 2006-07-19 三菱制药株式会社 喹唑啉衍生物
WO2003031406A2 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
CA2497971A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
WO2004069145A2 (en) 2003-02-07 2004-08-19 Dr. Reddy's Laboratories Ltd. Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
PA8603801A1 (es) 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
WO2005067667A2 (en) 2004-01-07 2005-07-28 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US8017321B2 (en) 2004-01-23 2011-09-13 The Regents Of The University Of Colorado, A Body Corporate Gefitinib sensitivity-related gene expression and products and methods related thereto
WO2006090717A1 (ja) * 2005-02-23 2006-08-31 Shionogi & Co., Ltd. チロシンキナーゼ阻害作用を有するキナゾリン誘導体

Also Published As

Publication number Publication date
NO20074311L (no) 2007-11-23
EP1854789A4 (en) 2009-06-17
US20090143414A1 (en) 2009-06-04
AU2006216266C1 (en) 2010-08-26
CA2599328C (en) 2012-04-17
RU2007135023A (ru) 2009-03-27
AU2006216266B2 (en) 2010-02-18
AU2006216266A2 (en) 2006-08-31
CA2599328A1 (en) 2006-08-31
EP1854789A1 (en) 2007-11-14
TW200640880A (en) 2006-12-01
EP1854789B1 (en) 2013-10-09
CN101163684A (zh) 2008-04-16
JP4137174B2 (ja) 2008-08-20
ES2431843T3 (es) 2013-11-28
CN101163684B (zh) 2012-08-29
DK1854789T3 (da) 2013-10-21
KR20070098941A (ko) 2007-10-05
US8349857B2 (en) 2013-01-08
AU2006216266A8 (en) 2009-04-02
PL1854789T3 (pl) 2014-03-31
TWI372147B (en) 2012-09-11
US8202879B2 (en) 2012-06-19
US20120123114A1 (en) 2012-05-17
JPWO2006090717A1 (ja) 2008-07-24
NO343403B1 (no) 2019-02-25
PT1854789E (pt) 2013-10-23
RU2414457C2 (ru) 2011-03-20
KR100910333B1 (ko) 2009-07-31
BRPI0606905B1 (pt) 2021-06-01
AU2006216266A1 (en) 2006-08-31
WO2006090717A1 (ja) 2006-08-31

Similar Documents

Publication Publication Date Title
BRPI0606905A2 (pt) derivados de quinazolina tendo atividade inibitória de tirosina cinase e composição farmacêutica contendo-os
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
DK1261602T3 (da) Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer
NO20023218L (no) 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20073956L (no) Pyrazolderivater for inhibering av CDK og GSK
BRPI0616574A2 (pt) derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
BR0313297A (pt) 6-alcóxi-pirido-pirimidinas como inibidores de p-38 map cinase
ATE205195T1 (de) Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren
MA31593B1 (fr) Derives de 2-aza-bicyclo[3.3.0]octane
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
BR0213452A (pt) Derivados de piperazina com atividade antagonista receptora de ccr1
BRPI0409255A (pt) derivados de ácido 2-(8,9-dioxo-2,6-diazabi-ciclo(5.2.0)non-1(7)-en-2-il)alquil fosfÈnico e seu uso como antagonistas de receptores de d-asparto de -n-metila (nmda)
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BRPI0418082B8 (pt) derivados de tiazol úteis como antagonistas de receptor de adenosina a2a
BRPI0418074B8 (pt) derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
BR0212435A (pt) Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
BR0310032A (pt) Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos
RS53183B (en) IMIDASOL DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS
BR0311960A (pt) Derivado de 1-[ (indol-3-il) carbonil] piperazina, uso do mesmo e composição farmacêutica
BR112023004550A2 (pt) Compostos tricíclicos substituídos
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
NO20014864D0 (no) Substituerte 1,4-dihydro-inden [1,2-C] pyrazoler som inhibitorer av tyrosin kinase

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/02/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF